RESUMEN
Type 1 diabetes mellitus (T1DM) is an autoimmune disorder specifically targeting pancreatic islet beta cells. Despite many efforts focused on identifying new therapies able to counteract this autoimmune attack and/or stimulate beta cells regeneration, TD1M remains without effective clinical treatments providing no clear advantages over the conventional treatment with insulin. We previously postulated that both the inflammatory and immune responses and beta cell survival/regeneration must be simultaneously targeted to blunt the progression of disease. Umbilical cord-derived mesenchymal stromal cells (UC-MSC) exhibit anti-inflammatory, trophic, immunomodulatory and regenerative properties and have shown some beneficial yet controversial effects in clinical trials for T1DM. In order to clarify conflicting results, we herein dissected the cellular and molecular events derived from UC-MSC intraperitoneal administration (i.p.) in the RIP-B7.1 mouse model of experimental autoimmune diabetes. Intraperitoneal (i.p.) transplantation of heterologous mouse UC-MSC delayed the onset of diabetes in RIP-B7.1 mice. Importantly, UC-MSC i. p. transplantation led to a strong peritoneal recruitment of myeloid-derived suppressor cells (MDSC) followed by multiple T-, B- and myeloid cells immunosuppressive responses in peritoneal fluid cells, spleen, pancreatic lymph nodes and the pancreas, which displayed significantly reduced insulitis and pancreatic infiltration of T and B Cells and pro-inflammatory macrophages. Altogether, these results suggest that UC-MSC i. p. transplantation can block or delay the development of hyperglycemia through suppression of inflammation and the immune attack.
RESUMEN
Tropical endomyocardial fibrosis (FET) is a leading cause of heart failure and the most common restrictive cardiomyopathy worldwide. Extensive fibrosis of the ventricular endocardium causing architectural distortion, impaired filling and valvular insufficiency define the disease. Confined to peculiar and limited geographical areas, the aetiology remains blurred and it carries a grim prognosis. The changing burden reported recently in some endemic areas and the refinement of diagnostic tools have emphasized alternative routes for understanding and treatment of the disease.
Asunto(s)
Fibrosis Endomiocárdica/diagnóstico , Fibrosis Endomiocárdica/epidemiología , Ventrículos Cardíacos/patología , África/epidemiología , Diagnóstico Diferencial , Humanos , Prevalencia , Pronóstico , Factores de RiesgoRESUMEN
In Parkinson's disease (PD) depletion of dopamine in the nigro-striatal pathway is a main pathological hallmark that requires continuous and focal restoration. Current predominant treatment with intermittent oral administration of its precursor, Levodopa (l-dopa), remains the gold standard but pharmacological drawbacks trigger motor fluctuations and dyskinesia. Continuous intracerebroventricular (i.c.v.) administration of dopamine previously failed as a therapy because of an inability to resolve the accelerated dopamine oxidation and tachyphylaxia. We aim to overcome prior challenges by demonstrating treatment feasibility and efficacy of continuous i.c.v. of dopamine close to the striatum. Dopamine prepared either anaerobically (A-dopamine) or aerobically (O-dopamine) in the presence or absence of a conservator (sodium metabisulfite, SMBS) was assessed upon acute MPTP and chronic 6-OHDA lesioning and compared to peripheral l-dopa treatment. A-dopamine restored motor function and induced a dose dependent increase of nigro-striatal tyrosine hydroxylase positive neurons in mice after 7days of MPTP insult that was not evident with either O-dopamine or l-dopa. In the 6-OHDA rat model, continuous circadian i.c.v. injection of A-dopamine over 30days also improved motor activity without occurrence of tachyphylaxia. This safety profile was highly favorable as A-dopamine did not induce dyskinesia or behavioral sensitization as observed with peripheral l-dopa treatment. Indicative of a new therapeutic strategy for patients suffering from l-dopa related complications with dyskinesia, continuous i.c.v. of A-dopamine has greater efficacy in mediating motor impairment over a large therapeutic index without inducing dyskinesia and tachyphylaxia.
Asunto(s)
Dopamina/administración & dosificación , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Infusiones Intraventriculares , Trastornos Parkinsonianos/tratamiento farmacológico , Índice de Severidad de la Enfermedad , Animales , Células Cultivadas , Dopamina/metabolismo , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Discinesia Inducida por Medicamentos/metabolismo , Humanos , Mesencéfalo/citología , Mesencéfalo/efectos de los fármacos , Mesencéfalo/metabolismo , Ratones , Ratones Endogámicos C57BL , Trastornos Parkinsonianos/metabolismo , Ratas , Ratas Wistar , Resultado del TratamientoRESUMEN
Recent studies suggested that the post-natal mesothelium retain differentiative potential of the embryonic mesothelium, which generates fibroblasts and vascular smooth muscle cells (VSMCs), in developing coelomic organs via epithelial-to-mesenchymal transition (EMT). Whether adult mesothelial cells (MCs) are able to give rise to functional VSMCs in vitro and which are the factors and mechanisms directing this process remain largely unknown. Here, we isolated adipose tissue MCs (ATMCs) from adult mice, and demonstrated that ATMCs cultured in a serum-containing media supplemented with epidermal growth factor (EGF) efficiently increased both their proliferation and EMT above levels found in only serum-containing media cultures. EGF-induced ATMCs gained phosphorylation of the EGF receptor and activated simultaneously ILK/Erk1/2, PI3K/Akt and Smad2/3-dependent pathways. Sequential subculture onto collagen-I surface efficiently improved their vasculogenic EMT towards cells featuring VSMCs (α-SMA, calponin, caldesmon, SM22α, desmin, SM-MHC, smoothelin-B and PDGFR-ß) that could actively contract in response to receptor and non-receptor-mediated vasoactive agonists. Overall, our results indentify EGF signalling as a robust vasculogenic inductive pathway for ATMCs, leading to their transdifferentiation into functional VSMC-like cells.
Asunto(s)
Tejido Adiposo/metabolismo , Diferenciación Celular/fisiología , Proliferación Celular/fisiología , Factor de Crecimiento Epidérmico/metabolismo , Músculo Liso Vascular/metabolismo , Miocitos del Músculo Liso/metabolismo , Tejido Adiposo/citología , Animales , Antígenos de Diferenciación/metabolismo , Células Cultivadas , Femenino , Ratones , Proteínas Musculares/metabolismo , Músculo Liso Vascular/citología , Miocitos del Músculo Liso/citología , Ratas , Ratas Wistar , Transducción de Señal/fisiologíaRESUMEN
In eukaryotic cells, sphingoid long chain bases (LCBs) such as sphingosine or phytosphingosine (PHS) behave as second messengers involved in various processes including programmed cell death (PCD). In plants, induction of PCD by LCBs has now been described, but the signalling pathway is still enigmatic. Using Arabidopsis, we identify new key steps in this pathway. We demonstrate that PHS induces activation of the calcium-dependent kinase CPK3, which phosphorylates its binding partners, the 14-3-3 proteins. This phosphorylation leads to the disruption of the complex and to CPK3 degradation. Using cpk3 knockout lines, we demonstrate that CPK3 is a positive regulator of LCB-mediated PCD. These findings establish 14-3-3-regulated CPK3 as a key component of the LCB pathway leading to PCD in plants.
Asunto(s)
Proteínas 14-3-3/metabolismo , Apoptosis/efectos de los fármacos , Proteínas de Arabidopsis/metabolismo , Arabidopsis/metabolismo , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Esfingosina/análogos & derivados , Proteínas de Arabidopsis/genética , Calcio/metabolismo , Proteínas Quinasas Dependientes de Calcio-Calmodulina/genética , Células Cultivadas , Técnicas de Inactivación de Genes , Lantano/farmacología , Fosforilación , Plantas Modificadas Genéticamente/metabolismo , Unión Proteica , Esfingosina/farmacologíaRESUMEN
This paper presents further international comparisons of progressivity of health care financing systems. The paper builds on the work of Wagstaff et al. [Wagstaff, A., van Doorslaer E., et al., 1992. Equity in the finance of health care: some international comparisons, Journal of Health Economics 11, pp. 361-387] but extends it in a number of directions: we modify the methodology used there and achieve a higher degree of cross-country comparability in variable definitions; we update and extend the cross-section of countries; and we present evidence on trends in financing mixes and progressivity.
Asunto(s)
Política de Salud/economía , Programas Nacionales de Salud/economía , Justicia Social , Impuestos/clasificación , Comparación Transcultural , Europa (Continente) , Finlandia , Alemania , Investigación sobre Servicios de Salud , Humanos , Renta/estadística & datos numéricos , Seguro de Salud/economía , Suecia , Impuestos/economía , Impuestos/estadística & datos numéricosRESUMEN
The OECD countries finance their health care through a mixture of taxes, social insurance contributions, private insurance premiums and out-of-pocket payments. The various payment sources have very different implications for both vertical and horizontal equity and on redistributive effect which is a function of both. This paper presents results on the income redistribution consequences of the health care financing mixes adopted in twelve OECD countries by decomposing the overall income redistributive effect into a progressivity, horizontal inequity and reranking component. The general finding of this study is that the vertical effect is much more important than horizontal inequity and reranking in determining the overall redistributive effect but that their relative importance varies by source of payment. Public finance sources tend to have small positive redistributive effects and less differential treatment while private financing sources generally have (larger) negative redistributive effects which are to a substantial degree caused by differential treatment.
Asunto(s)
Política de Salud/economía , Programas Nacionales de Salud/economía , Justicia Social , Impuestos/clasificación , Comparación Transcultural , Europa (Continente) , Financiación Personal/estadística & datos numéricos , Investigación sobre Servicios de Salud , Humanos , Seguro de Salud/economía , Modelos Econométricos , Impuestos/economía , Impuestos/estadística & datos numéricosRESUMEN
This paper presents the results of an eight-country comparative study of equity in the delivery of health care. Equity is taken to mean that persons in equal need of health care should be treated the same, irrespective of their income. Two methods are used to investigate inequity: an index of inequity based on standardized expenditure shares, and a regression-based test. The results suggest that inequity exists in most of the eight countries, but there is no simple one-to-one correspondence between a country's delivery system and the degree to which persons in equal need are treated the same.
Asunto(s)
Atención a la Salud/economía , Accesibilidad a los Servicios de Salud/economía , Internacionalidad , Justicia Social/economía , Comparación Transcultural , Atención a la Salud/normas , Atención a la Salud/estadística & datos numéricos , Europa (Continente) , Gastos en Salud/estadística & datos numéricos , Accesibilidad a los Servicios de Salud/normas , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Investigación sobre Servicios de Salud , Renta/clasificación , Seguro de Salud/economía , Seguro de Salud/normas , Seguro de Salud/estadística & datos numéricos , Modelos Econométricos , Programas Nacionales de Salud/economía , Programas Nacionales de Salud/normas , Programas Nacionales de Salud/estadística & datos numéricos , Análisis de Regresión , Factores Socioeconómicos , Medicina Estatal/economía , Medicina Estatal/normas , Medicina Estatal/estadística & datos numéricos , Estados UnidosRESUMEN
This paper presents the results of a ten-country comparative study of health care financing systems and their progressivity characteristics. It distinguishes between the tax-financed systems of Denmark, Portugal and the U.K., the social insurance systems of France, the Netherlands and Spain, and the predominantly private systems of Switzerland and the U.S. It concludes that tax-financed systems tend to be proportional or mildly progressive, that social insurance systems are regressive and that private systems are even more regressive. Out-of-pocket payments are in most countries an especially regressive means of raising health care revenues.